Author:
Galetta Kristin,Ham Andrew Siyoon,Vishnevetsky Anastasia,Bhattacharyya Shamik,Mateen Farrah J.
Reference27 articles.
1. Tumefactive demyelinating lesions: a comprehensive review;Algahtani;Mult. Scler. Relat. Disord.,2017
2. Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures;Alvarez;Mult. Scler. J. - Exp. Transl. Clin.,2015
3. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis;Barkhof;Brain J. Neurol.,1997
4. Ocrelizumab in tumefactive multiple sclerosis onset. A case report;Bazzurri;Neuroimmunol. Rep.,2022
5. The elimination of circulating Epstein-Barr virus infected B cells underlies anti-CD20 monoclonal antibody activity in multiple sclerosis: a hypothesis;Berger;Mult. Scler. Relat. Disord.,2022